HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survey Shows European Consumers Still Want CBD, But Manufacturers Can Do More

Executive Summary

European demand fror cannabidiol wellness products will continue to expand in the future, but manufacturers can do more to drive growth, says cannabis experts Prohibition Partners. 

You may also be interested in...



Offset-Based Green Claims Like 'Carbon Neutral' Will Soon Be Banned In Europe

The Green Claims Directive has moved one step closer to becoming European Union law. Once passed, within 24 months CO2 offset-based claims like "carbon neutral" will be banned altogether, claims like “environmentally friendly” will require substantive backing and sustainability labels in general will need to be approved beforehand by certification schemes or public authorities. 

Get To Know: Rising UK Effervescent Wellness Star Phizz

London-based start-up Phizz markets in the UK's busy wellness category effervescent products that it claims effectively hydrate while also providing essential vitamins and minerals.

Italy Reclassifies Natural CBD Oil As Medicine Containing Narcotic

Italy reclassifies natural CBD as a narcotic drug. The decision may see challenges from companies marketing in Italy natural CBD supplements registered in other European countries, given that the European Court of Justice (CJEU) overturned a similar position taken by France in 2020.  

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel